Table 2 Surgical parameters of 559 advanced EOC patients having cytoreductive surgery. A total of 185, 194, and 180 patients were treated during the baseline, transition, and evaluation years, respectively. Numbers are shown either as absolute numbers with percentage unless otherwise indicated

Surgical cytoreduction

0.254

 PDS

49 (26.5%)

60 (30.9%)

62 (34.4%)

 IDS

136 (73.5%)

134 (69.1%)

118 (65.6%)

PCI^a

Median (Range)

4 (1–8)

8 (1–24)

8 (2–21)

< 0.0001

Dissemination (GOG)^b

0.408

 MD

17 (9.2%)

17 (8.8%)

19 (10.6%)

 APD

110 (59.2%)

102 (52.6%)

90 (50.0%)

 UAD

58 (31.3%)

75 (38.6%)

71 (39.4%)

Surgical Complexity Score (SCS)

< 0.00001

 Low (1–3)

135 (73.0%)

110 (56.7%)

74 (41.1%)

 Intermediate (4–7)

49 (26.5%)

68 (35.1%)

84 (46.7%)

 High (8–18)

1 (0.5%)

16 (8.2%)

22 (12.2%)

Specialist Surgeons Involved^c

< 0.0001

 One Gyne-Onc

164 (88.6%)

92 (47.4%)

106 (58.9%)

 Two Gyne-Onc’s

9 (4.9%)

72 (37.1%)

40 (22.2%)

 Gyne-Onc & GI

12 (6.5%)

21 (10.8%)

26 (14.5%)

 Gyne-Onc & HPB

 Gyne-Onc & GI & HPB

0

0

5 (2.6%)

4 (2.1%)

4 (2.2%)

4 (2.2%)

Residual Disease (RD)^d

0.0041

 CC 0 (nil RD)

104 (56.2%)

127 (65.5%)

135 (75.0%)

 CC 1 (0 mm < RD < 2.5 mm)

33 (17.8%)

21 (10.8%)

23 (12.8%)

 CC 2 (2.5 mm ≤ RD < 2.5 cm)

32 (17.3%)

29 (14.9%)

17 (9.4%)

 CC 3 (RD ≥ 2.5 cm)

16 (8.7%)

17 (8.8%)

5 (2.8%)

Blood Loss (mL)

Mean ± SD

469 ± 321

549 ± 362

551 ± 464

0.109